Skip to content
LPCNLipocine Inc.

Earnings

When Lipocine Inc. reports, what it reported each quarter, and how the stock took the results.

61 quarters. Sep 30, 2011 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 9, before the open

Tue, Mar 9, 2027in 113 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 5 – 16

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$1.15M
Revenue, change from a year earlier: Q3 2026 +1,898.8%, Q2 2026 −69.5%, Q1 2026 +27.2%, Q4 2025 −67.2%
Net income
-$2.37M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$2.29M+1,898.8% vs Q3 2025

Latest results

  1. Q3 2026Nov 5, 2026, during market hoursThe release+4.8%by the close of Nov 5
    Revenue
    $2.29M
    +1,898.8%
    Net income
    -$666.19K
    N/M
    EPS
    -$0.08
    N/M
    Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results for the third quarter ended September 30, 2026 and provided a corporate update.
  2. Q2 2026Aug 4, 2026, before the openThe release+3.3%by the close of Aug 4
    Revenue
    $190.10K
    −69.5%
    Net income
    -$2.62M
    N/M
    EPS
    -$0.32
    N/M
  3. Q1 2026May 7, 2026, before the openThe release1.2%by the close of May 7
    Revenue
    $119.40K
    +27.2%
    Net income
    -$3.67M
    N/M
    EPS
    -$0.54
    N/M
  4. Q4 2025Mar 9, 2026, after the closeThe release+1.4%by the close of Mar 10
    Revenue
    $1.15M
    −67.2%
    Net income
    -$2.37M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 5, 2026 · market hoursNov 5, 202636 d10-Q$2.29M+1,898.8%-$0.08+4.8%
Q2 2026Jun 30, 2026Aug 4, 2026 · pre-marketAug 4, 202635 d10-Q$190.10K−69.5%-$0.32+3.3%
Q1 2026Mar 31, 2026May 7, 2026 · pre-marketMay 7, 202637 d10-Q$119.40K+27.2%-$0.541.2%
FY 2025
Q4 2025derivedDec 31, 2025Mar 10, 2026 · pre-marketMar 10, 202669 d10-K$1.15M−67.2%—+1.4%
Q3 2025Sep 30, 2025Nov 6, 2025 · market hoursNov 6, 202537 d10-Q$114.57K—-$0.59—
Q2 2025Jun 30, 2025Aug 5, 2025 · pre-marketAug 5, 202536 d10-Q$622.85K+595.4%-$0.412.5%
Q1 2025Mar 31, 2025—May 8, 202538 d10-Q$93.86K−98.8%-$0.351.3%
FY 2024
Q4 2024derivedDec 31, 2024—Mar 13, 202572 d10-K$3.49M+1,515.0%——
Q3 2024Sep 30, 2024—Nov 7, 202438 d10-Q——-$0.4420.5%
Q2 2024Jun 30, 2024—Aug 8, 202439 d10-Q$89.57K—-$0.5611.4%
Q1 2024Mar 31, 2024—May 9, 202439 d10-Q$7.62M+13,751.9%$0.66—
Earlier years, FY 2011 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 5, 2026050097
10-QAug 4, 2026035909
10-QMay 7, 2026021637
10-KMar 10, 2026009411
10-QNov 6, 2025021007
10-QAug 5, 2025011588
10-QMay 8, 2025009180
10-KMar 13, 2025010146
10-QNov 7, 2024043893
10-QAug 8, 2024030648

Provenance

ProvenanceData status and checks

Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR